Residents and Fellows Research in Progress
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Introduction:
Synthetic angiotensin II is a commercially available vasoactive peptide used for increasing blood pressure in distributive shock states, including post-cardiac surgery vasoplegia. Due to its high cost and association with increased risk for thrombotic events, angiotensin II is a restricted item within Baylor University Medical Center (BUMC), with stringent criteria for its use. Rates of adherence to these criteria, as well as optimal operational processes to reduce costs and waste, have not been evaluated.
Research Question or Hypothesis:
What is the rate of adherence to formulary criteria for use of angiotensin II at BUMC?
Study Design:
Retrospective, observational cohort study
Methods:
Data will be collected from the last 100 consecutive patients receiving angiotensin II at BUMC. Retrospective chart review will be performed to identify baseline characteristics related to formulary criteria, outcomes associated with the efficacy and safety of angiotensin II, the quantity used by each patient, and the amount of waste generated. The primary outcome will be rate of adherence to formulary criteria. Secondary outcomes will include blood pressure raising effects, incidence of thromboembolic events, cost and quantity of drug used, and the amount of cumulative drug waste.
Results:
Results are in process pending data collection and analysis. Results will be reported as means (standard deviation) for continuous parametric data, median [inter-quartile range] for continuous non-parametric data, and percentages for discrete outcomes. Post hoc statistical comparisons may be conducted based on trends recognized from collected data.
Conclusion:
Conclusions will be determined based on the results of data collection and analysis.
Presenting Author
Trenton Flanagan Pharm.D.University of Oklahoma College of Pharmacy
Authors
Nelson Akwo Pharm.D
Baylor University Medical Center
Kjersti Fry Pharm.D.
Baylor University Medical Center
Roberto Montealegre Pharm.D.
Baylor University Medical Center